Brind.

IQVIA and Medpace reported strong earnings amid industry rebound, while China remains a key source of raw ingredients.

2 reports, 2 independent Updated Jul 25
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

IQVIA and Medpace reported strong earnings amid industry rebound, while China remains a key source of raw ingredients.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • ReutersContract research firms' strong earnings signal stabilizing biotech, pharma spending By Sneha S K (Reuters) -Contract research organizations are reporting better-than-expected second-quarter profit,
  • GuruFocus.comMedpace Holdings Inc (MEDP) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... Revenue: $603.3 million for Q2 2025, a 14.2% year-over-year increase. Net New Business Awards: $620.